Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Evolus, Inc.

EOLSNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$5.04
$0.03(0.60%)
U.S. Market opens in 15h 58m

Evolus, Inc. Fundamental Analysis

Evolus, Inc. (EOLS) shows moderate financial fundamentals with a PE ratio of -6.18, profit margin of -17.38%, and ROE of 2.68%. The company generates $0.3B in annual revenue with strong year-over-year growth of 31.76%.

Key Strengths

Cash Position16.57%
PEG Ratio-0.52
Current Ratio1.90

Areas of Concern

ROE2.68%
Operating Margin-12.65%
We analyze EOLS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 122.4/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.

Fundamental Health Score

A
122.4/100

We analyze EOLS's fundamental strength across five key dimensions:

Efficiency Score

Weak

EOLS struggles to generate sufficient returns from assets.

ROA > 10%
-22.86%

Valuation Score

Excellent

EOLS trades at attractive valuation levels.

PE < 25
-6.18
PEG Ratio < 2
-0.52

Growth Score

Excellent

EOLS delivers strong and consistent growth momentum.

Revenue Growth > 5%
31.76%
EPS Growth > 10%
25.00%

Financial Health Score

Excellent

EOLS maintains a strong and stable balance sheet.

Debt/Equity < 1
-6.71
Current Ratio > 1
1.90

Profitability Score

Weak

EOLS struggles to sustain strong margins.

ROE > 15%
267.84%
Net Margin ≥ 15%
-17.38%
Positive Free Cash Flow
No

Key Financial Metrics

Is EOLS Expensive or Cheap?

P/E Ratio

EOLS trades at -6.18 times earnings. This suggests potential undervaluation.

-6.18

PEG Ratio

When adjusting for growth, EOLS's PEG of -0.52 indicates potential undervaluation.

-0.52

Price to Book

The market values Evolus, Inc. at -13.81 times its book value. This may indicate undervaluation.

-13.81

EV/EBITDA

Enterprise value stands at -7.99 times EBITDA. This is generally considered low.

-7.99

How Well Does EOLS Make Money?

Net Profit Margin

For every $100 in sales, Evolus, Inc. keeps $-17.38 as profit after all expenses.

-17.38%

Operating Margin

Core operations generate -12.65 in profit for every $100 in revenue, before interest and taxes.

-12.65%

ROE

Management delivers $2.68 in profit for every $100 of shareholder equity.

2.68%

ROA

Evolus, Inc. generates $-22.86 in profit for every $100 in assets, demonstrating efficient asset deployment.

-22.86%

Following the Money - Real Cash Generation

Operating Cash Flow

Evolus, Inc. generates limited operating cash flow of $-42.65M, signaling weaker underlying cash strength.

$-42.65M

Free Cash Flow

Evolus, Inc. generates weak or negative free cash flow of $-48.90M, restricting financial flexibility.

$-48.90M

FCF Per Share

Each share generates $-0.75 in free cash annually.

$-0.75

FCF Yield

EOLS converts -15.00% of its market value into free cash.

-15.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-6.18

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.52

vs 25 benchmark

P/B Ratio

Price to book value ratio

-13.81

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.08

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-6.71

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.90

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

2.68

vs 25 benchmark

ROA

Return on assets percentage

-0.23

vs 25 benchmark

ROCE

Return on capital employed

-0.25

vs 25 benchmark

How EOLS Stacks Against Its Sector Peers

MetricEOLS ValueSector AveragePerformance
P/E Ratio-6.1828.25 Better (Cheaper)
ROE267.84%780.00% Weak
Net Margin-17.38%-20122.00% (disorted) Weak
Debt/Equity-6.710.30 Strong (Low Leverage)
Current Ratio1.904.66 Neutral
ROA-22.86%-14687.00% (disorted) Weak

EOLS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Evolus, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

247.15%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

74.50%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

91.22%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ